接受玻璃体腔注射阿柏西普或雷珠单抗治疗的年龄相关性黄斑变性患者对侧眼新发脉络膜新生血管的发生率
该研究为VIEW 1和VIEW 2试验的事后分析,纳入1561例单眼接受抗VEGF治疗且对侧眼基线无新生血管的nAMD患者。96周时对侧眼转化为新生血管性AMD的总发生率为24.0%(375例),各治疗组每100患者年风险率分别为18.1、16.2、14.7和16.0。多因素分析显示年龄增长、女性、研究眼基线视网膜内液和研究眼基线脉络膜新生血管病灶较大与对侧眼转化相关,两种治疗组间转化率相似。
要点
- 96周时对侧眼转化为新生血管性AMD的总发生率为24.0%(375/1561例)。
- 各治疗组每100患者年风险率:雷珠单抗0.5mg每4周组18.1,阿柏西普2mg每4周组16.2,阿柏西普0.5mg每4周组14.7,阿柏西普2mg每8周组16.0。
- 多因素分析显示年龄每增加10岁(HR 1.20)、女性(HR 1.32)、研究眼基线视网膜内液(HR 1.28)和研究眼基线CNV病灶每增加10mm²(HR 1.29)与对侧眼转化相关。
核心结论
- 在这项随机临床试验数据的二次分析中,单眼活动性nAMD患者对侧眼转化风险似乎较高,此类患者应密切监测。
研究设计与样本
- VIEW 1和VIEW 2研究的事后分析,两项随机、双盲、活性对照、多中心、96周、3期试验比较玻璃体腔阿柏西普在2457例治疗初治nAMD患者中的疗效与安全性。
- 分析纳入单眼接受nAMD治疗且对侧眼基线无新生血管化的亚组参与者,共1561例。
- 参与者被纳入四组之一:雷珠单抗0.5mg每4周、阿柏西普2mg每4周、阿柏西普0.5mg每4周、或阿柏西普2mg每4周注射3次后每8周。
- VIEW研究数据收集时间为2007年7月至2011年8月;本报告数据分析时间为2016年4月至2018年11月。
主要发现
- 96周时,375例患者(24.0%)对侧眼转化为新生血管性疾病,其中雷珠单抗0.5mg每4周组107/399例、阿柏西普2mg每4周组93/387例、阿柏西普0.5mg每4周组84/387例、阿柏西普2mg每8周组91/388例。
- 96周时每100患者年风险率分别为18.1、16.2、14.7和16.0。
- 多因素分析显示对侧眼转化与基线年龄每增加10岁(HR 1.20 [95%CI 1.05-1.36])、女性(HR 1.32 [95%CI 1.06-1.63])、研究眼基线视网膜内液(HR 1.28 [95%CI 1.02-1.61])和研究眼基线脉络膜新生血管病灶每增加10mm²(HR 1.29 [95%CI 1.06-1.57])相关。
- 两种治疗的对侧眼转化率相似。
临床怎么用
- 作者认为,单眼活动性nAMD患者对侧眼转化风险似乎较高,此类患者应密切监测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Incidence of conversion to neovascular age-related macular degeneration (nAMD) in untreated fellow eyes of patients who are treated for nAMD in 1 eye with anti-vascular endothelial growth factor agents provides important prognostic information to clinically manage patients. OBJECTIVE: To investigate the association of treatment assignment (intravitreal aflibercept vs ranibizumab) and baseline characteristics with fellow eye conversion to nAMD in the VEGF (Vascular Endothelial Growth Factor) Trap-Eye: Investigation of Efficacy and Safety in Wet AMD (VIEW) studies. DESIGN, SETTING, AND PARTICIPANTS: This post hoc analysis of the VIEW 1 and VIEW 2 studies (randomized, double-masked, active-controlled, multicenter, 96-week, phase 3 trials comparing the efficacy and safety of intravitreal aflibercept in 2457 patients with treatment-naive eyes with nAMD) analyzed a subgroup of participants treated for nAMD in 1 eye who had untreated fellow eyes without neovascularization at baseline. All participants in the VIEW studies were included in 1 of 4 groups: ranibizumab, 0.5 mg, every 4 weeks; aflibercept, 2 mg, every 4 weeks; aflibercept, 0.5 mg, every 4 weeks; or aflibercept, 2 mg, every 8 weeks after 3 injections at 4-week intervals. Data collection in the VIEW studies occurred from July 2007 to August 2011; the data analysis presented in this report took place from April 2016 to November 2018. INTERVENTIONS: Patients received no treatment in the fellow eyes unless after conversion to nAMD, when any treatment approved by heath authorities was given per the investigators' discretion. MAIN OUTCOMES AND MEASURES: Incidence of conversion to nAMD in patients with untreated fellow eyes that had not had clinical signs of neovascularization at baseline. RESULTS: A total of 1561 participants were included in this analysis. At 96 weeks, 375 patients (24.0%) experienced cases of conversion to neovascular disease in the fellow eye, including 107 of the 399 individuals who received ranibizumab, 0.5 mg, every 4 weeks; 93 of the 387 individuals who received aflibercept, 2 mg, every 4 weeks; 84 of the 387 individuals who received aflibercept, 0.5 mg, every 4 weeks; and 91 of the 388 individuals who received aflibercept, 2 mg, every 8 weeks after 3 doses at 4-week intervals. The rates were 18.1, 16.2, 14.7, and 16.0 per 100 patient-years at risk at week 96, respectively. On multivariate analysis, fellow eye conversion was associated with increasing patient age (per 10 years) at baseline (hazard ratio [HR], 1.20 [95% CI, 1.05-1.36]), female sex (HR, 1.32 [95% CI, 1.06-1.63]), intraretinal fluid in the study eye at baseline (HR, 1.28 [95% CI, 1.02-1.61]), and increasing choroidal neovascularization lesion size (per 10 mm2) in the study eye at baseline (HR, 1.29 [95% CI, 1.06-1.57]). Rates of fellow eye conversion were similar with either of the treatments. CONCLUSIONS AND RELEVANCE: In this secondary analysis of randomized clinical trial data, patients with active nAMD in 1 eye appeared to have a high risk for fellow eye conversion. Such patients should be monitored closely.
引用
- Parikh R, Avery RL, Saroj N, et al. Incidence of New Choroidal Neovascularization in Fellow Eyes of Patients With Age-Related Macular Degeneration Treated With Intravitreal Aflibercept or Ranibizumab. JAMA Ophthalmol. 2019. PMID: 31294771. doi:10.1001/jamaophthalmol.2019.1947
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。